Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $3,221,132.67 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 87,507 shares of Dianthus Therapeutics stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $36.81, for a total value of $3,221,132.67. Following the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $147,240. This trade represents a 95.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Simrat Randhawa also recently made the following trade(s):

• On Friday, November 14th, Simrat Randhawa sold 109,031 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $38.14, for a total value of $4,158,442.34.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $40.85 on Monday. The stock’s 50-day simple moving average is $35.94 and its 200-day simple moving average is $25.67. The firm has a market capitalization of $1.75 billion, a PE ratio of -11.74 and a beta of 1.56. Dianthus Therapeutics, Inc. has a fifty-two week low of $13.36 and a fifty-two week high of $41.15.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.11). Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.58 million. On average, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on DNTH shares. HC Wainwright lifted their price target on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Robert W. Baird lifted their target price on Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 9th. Stifel Nicolaus boosted their target price on Dianthus Therapeutics from $52.00 to $65.00 and gave the company a “buy” rating in a report on Friday, September 12th. Truist Financial assumed coverage on Dianthus Therapeutics in a research note on Tuesday, October 14th. They set a “buy” rating and a $56.00 price target on the stock. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $63.00 price target (up previously from $56.00) on shares of Dianthus Therapeutics in a research report on Tuesday, September 9th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $63.43.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vestal Point Capital LP grew its stake in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. RA Capital Management L.P. lifted its stake in shares of Dianthus Therapeutics by 53.6% in the 1st quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company’s stock worth $52,003,000 after acquiring an additional 1,000,333 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Dianthus Therapeutics by 3,366.9% in the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after acquiring an additional 2,503,311 shares in the last quarter. Octagon Capital Advisors LP boosted its holdings in shares of Dianthus Therapeutics by 11.0% in the first quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company’s stock valued at $42,478,000 after acquiring an additional 231,500 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Dianthus Therapeutics by 13.6% during the third quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock worth $64,620,000 after acquiring an additional 196,117 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.